A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Israel Digital Health Delegation to JPM Week 2022 | |||||||||||||||||||
2 | Company | One-liner | Description | Tech Tags | Therapeutic areas | Company stage | Funding raised (USD) | Revenue (USD) | Notable customers/partners | Looking to raise (USD) | FDA approval or clearance | US presence | Deck | Product Demo | ||||||
3 | Agamon | Powering data-driven healthcare, where no patient falls through the cracks | Powered by proprietary Natural Language Processing, Agamon technology can increase early detection of disease, detect follow-up recommendations in radiology reports, notifies the necessary people at the right time and tracks whether a patient has returned for their exams/follow-up appointments. | Artificial Intelligence, Clinical Document Management, Hospital Operational Efficiency | General Health, Oncology | Initial Revenues | $3.5M from MMC, Inhealth Ventures, Seedcamp and Bayer plus $500k grant from the IIA | Yes, to be shared during the meeting | Henry Ford Health System, Jefferson Health System, Main Street Radiology | $8M | Not required | US office in Atlanta where our GM US is based | Link | Link | ||||||
4 | DayTwo | Microbiome-based precision nutrition for metabolic disease | DayTwo uses the worlds most advanced proprietary microbiome science with access to the largest dataset to provide precision nutrition. DayTwo uses gut microbiome profiling and artificial intelligence to predict blood sugar response to foods and provide dedicated virtual care. Telehealth provides virtual care by registered dietitian Clinical & science based- published in peer reviewed journals our clinical study with significant results. The technology also tracks exams/follow-up appointments. | Nutrition Tech, Precision / Personalized Medicine, Telemedicine Solutions | Diabetics, Metabolic Diseases, Obesity | Revenue Growth | ~$85M | Yes, to be shared during the meeting | United , Cigna | $20-30M | Not required | Yes. Office in CA & Nusville, ~50 employees in US | Link | Link | ||||||
5 | DiA Imaging Analysis | Empowering Ultrasound Users with AI software solutions | DiA Imaging Analysis makes the use and analysis of ultrasound images smarter and accessible to all through the addition of AI-based technology. Instead of the subjective visual analysis performed currently, DiA’s Al-based solutions enable users to identify clinical indications and abnormalities objectively and accurately. | Artificial Intelligence, Decision Support Systems, Digital Imaging | Cardiovascular, Intensive Care, Primary Care | Initial Revenues | 25M | yes, disclosed upon meeting | n/a | 30M | Yes | Yes | Link | Link | ||||||
6 | Donisi Health | At home contact-free technology to remotely detect signs of pulmonary congestion and other parameters for heart failure. | Donisi has the only clinically validated contact-free technology that can remotely detect signs of pulmonary congestion and additional parameters key for heart failure exacerbation detection in the home. | Decision Support Systems, Remote Monitoring, Telemedicine Solutions | Cardiovascular | Initial Revenues | $27M | No | Dell, NUHS | $15M | Yes | Yes - one and growing! | Link | n/a | ||||||
7 | DreaMed Diabetes | AI-based decision support system for optimal diabetes treatment | DreaMed Diabetes’ endo.digital platform uses the company’s MD Logic algorithm to solve the massive lack of endocrinologists in the world and to provide ongoing diabetes expert care. Designed by premier endocrinologists, based on real-world evidence and charged by artificial intelligence, DreaMed is the only FDA-cleared software to manage and monitor diabetes by reading and analyzing continuous glucose monitors. The proprietary AI-based decision support system enables endocrinologists and non-specialists to rapidly prescribe recommended insulin doses. | Artificial Intelligence, Decision Support Systems, Precision / Personalized Medicine | Diabetics, Endocrinology | Initial Revenues | $2 Medtronic Diabetes, $3M Roman Abramovithc, $1.1M OurCrowd, $4.5M grant from the Helmsley Charitable Trust | yes, 2022 contract signed 1M | Boston Children's | $6-$10M | Yes | We have a US subsidiary entity with 2-5 employees | Link | Link | ||||||
8 | EyeControl | ICU communication platform enabling connectivity between ventilated patients, medical teams, and families. | EyeControl-Med is a communication solution for ICUs, enabling connectivity between patients who cannot speak, medical teams, and families. EyeControl-Med provides medical insight that enhances treatment accuracy, while increasing patient engagement. With the potential to manage Delirium, EyeControl-Med may decrease hospital costs and length of stay. | Artificial Intelligence, Nursing Applications, Wearables & IOT | Intensive Care, Neuroscience, Respiratory | Initial revenues and clinical trials. | $15M | Yes, to be shared during the meeting | Israeli Health Basket, Clalit, NHS | $15M | Yes | Office and 2 team members. | Link | Link | ||||||
9 | Geneyx Genomex Ltd | A superior Clinical Genetic data analysis, secure storage and management software | Geneyx offers a superior NGS data analysis and interpretation platform, harnessing genetic data to guide digital insights for rare and germline disorders.The AI-based analysis platform streamlines the diagnostics process, from the raw genetic data to the final clinical report. Geneyx develops unique technologies and utilizes diverse databases in the interpretation of WGS (Whole Genome Sequencing), WES, and gene panels. | Decision Support Systems, Hospital Operational Efficiency, Precision / Personalized Medicine | Cardiovascular, Genetic Disorders, Pediatrics | Revenue Growth | $10 M - Next leap venture, Capri ventures, Accenture ventures | yes, 750k | Accenture - life science division, Bambino Gesu children hospital, (Rome) Son Espace hospital (Spain) | $10M | Not required | Geneyx INC. 1013 Centre Road, Suite 403-B Wilmington, DE USA 19805, 4 employees | Link | Link | ||||||
10 | MedAware | AI-Powered Medication Safety Platform | MedAware's AI-powered medication safety monitoring platform identifies dangerous medication-related risks throughout the entire patient journey. The platform lives within existing technology systems, EHRs, and other devices. Built using longitudinal and real-time patient data, advanced machine learning algorithms identify medication errors, opioid dependency risk, evolving adverse drug events, drug-drug interactions and more. Founded in 2012, MedAware has offices in the United States and Israel. | Artificial Intelligence, Decision Support Systems, Population Health Management | General Health, Internal Medicine, Primary Care | Revenue Growth | $20m OurCrowd, Qure Ventures, Winton Ventures, Gefen Capital | Yes, to be shared during the meeting | Baxter, Sheba Medical Center, athenahealth | $10M | Not Required | No | Link | Link | ||||||
11 | Medorion | Platform that learns members health behaviors and creates personalized programs/assistance based on this data. | The Health Behavior Management Platform enables health organizations to understand “real life” health behavior scenarios and manage every interaction with a member based on that Health report. These capabilities enable solving gaps in healthcare outcomes and improving the well-being of millions of individuals. | Artificial Intelligence, Population Health Management | General Health | Proof of Concept | $9M: 10D, TAU Ventures, iAngels | yes, 2-3M | Advantasure, BCBSMI, Pfizer Inc, | $15M | Not required | Medorion Technologies Inc, 3 employees | Link | n/a | ||||||
12 | Newstem | Proprietary Robust Bio-Platform for drug discovery | NewStem possess a proprietary and patented Haploid human Embryonic Stem Cells (HhESC) Atlas. This technology is the most Robust Tool for Genetic Screening. Utilizing this un-biased platform, the company is focused on developing cancer therapeutics based on Novel Targets for Synthetic Lethal Interaction | Precision / Personalized Medicine | Oncology | R&D | $4M NovelStem | No | Illumina | $10M | No | n/a | Link | Link | ||||||
13 | Olive Diagostics | First at home handsfree passve urinalysis device that enables continous monitoring | A noninvasive passive urinalysis sensor that provides real-time health alerts, early detection, and information on disease progression. Using optics for data collection, the sensor is mounted inside the toilet and does not require further intervention. | home health, wellness, urinalysis, IoT, | Chronic disease management | Round A | disclosed upon meeting | No | Israel Innovation Authority, Cleveland Clinic, Amgen, Maccabi Healthcare, Services, eHealth Ventures | disclosed upon meeting | Technostat (3rd party validation), ISO 13485 Certified | Coming Soon! | Link | Please Schedule | ||||||
14 | OncoHost | Blood-sample based profiling platform that predicts patient’s response to treatment | OncoHost developed a differentiated approach to precision oncology with excellent clinical results, significant value proposition and a working business model. OncoHost is supported by a world class SAB and experienced management. Commercial launch in the US at Q2 22 | Artificial Intelligence, Decision Support Systems, Precision / Personalized Medicine | Oncology | Clinical Trials | $15M | No | CMEH, TRDF, Glenrock, Value acceleration group inc. | $25 | Not Required | No | Link | Link | ||||||
15 | Owlytics | Validated Personal health analytics and triage based on off-the-shelf wearables | Predictive and personalized health analytics B2B service, supporting home health providers of fragile seniors, degenerative neurology patients and rehab patients. This technology continuously tracks the personal physiology/ activity/ gait/ fall and risk patterns of individuals, creating a powerful tool for risk management, indoor and outdoor. Our cloud-based predictive analytics were developed and validated in an academic center specializing in Neurodynamic and Fall risk management. Initial US market traction is also supported by CMS RPM & RTM reimbursement. | Artificial Intelligence, Remote Monitoring, Wearables & IOT | Neurology and Degenerative Disease, Primary Care, Rehabilitation | Initial Revenues | $6M funding +$2M grants. Investors: Halma CVC, CBG PE, Dovel Group, Mike Berman | yes, 500K | CareOne, Parkinson Pharma Company, LinkHome Therapy, BT, Centrak, Sheba Medical Center, Tel-Aviv Medical Center, Israeli HC Ministry | $10M | Yes, Neuro Progression 510k- End of 2022 | Boston, #3 BD/ Sales Team | Link | Link | ||||||
16 | Virility Medical Ltd | A consumer healthcare startup, focused on commercialization of sexual wellbeing products. | The product is the world’s first wearable, drug-free, single-use, discreet skin patch with an immediate effect of delaying ejaculation. Applied to the male perineum during intercourse, it delivers short-duration, low-intensity electrical stimulation, which enhances the strength and duration of volitional pelvic-floor muscle contractions, intended to delay ejaculation. The patch has been cleared by FDA and is CE-marked. Patents has been granted in the US, China, Japan and Australia. | Proactive welless/Lifestyle/Patient Engagment, Wearables & IOT | Urology | Regulatory Approval | USD 10M from Atkin Holdings https://www.arkinholdings.com/ | No | USD 30M Series B | Yes | Coming Soon! | Link | Link | |||||||
17 | Xtrodes | bio-convergence company, the developer of the first scalable wireless Smart Skin | X-trodes aims to reduce hospitals workload through a medical technology that provides advanced electrophysiological monitoring and analytics in patient’s natural environment. X-trodes Smart Skin, precisely and seamlessly provides multimodality measurements (EEG, ECG and EMG signals) and provides real-time display of the acquired signals through a single patch. | Artificial Intelligence, Remote Monitoring, Telemedicine Solutions | Neurology and Degenerative Disease, Neuroscience | Seed | 4.7M | yes, 500k | N/A | 10M | In 9-12 months | No | Link | n/a | ||||||
18 | ||||||||||||||||||||
19 | ||||||||||||||||||||
20 | ||||||||||||||||||||
21 | ||||||||||||||||||||
22 | ||||||||||||||||||||
23 | ||||||||||||||||||||
24 | ||||||||||||||||||||
25 | ||||||||||||||||||||
26 | ||||||||||||||||||||
27 | ||||||||||||||||||||
28 | ||||||||||||||||||||
29 | ||||||||||||||||||||
30 | ||||||||||||||||||||
31 | ||||||||||||||||||||
32 | ||||||||||||||||||||
33 | ||||||||||||||||||||
34 | ||||||||||||||||||||
35 | ||||||||||||||||||||
36 | ||||||||||||||||||||
37 | ||||||||||||||||||||
38 | ||||||||||||||||||||
39 | ||||||||||||||||||||
40 | ||||||||||||||||||||
41 | ||||||||||||||||||||
42 | ||||||||||||||||||||
43 | ||||||||||||||||||||
44 | ||||||||||||||||||||
45 | ||||||||||||||||||||
46 | ||||||||||||||||||||
47 | ||||||||||||||||||||
48 | ||||||||||||||||||||
49 | ||||||||||||||||||||
50 | ||||||||||||||||||||
51 | ||||||||||||||||||||
52 | ||||||||||||||||||||
53 | ||||||||||||||||||||
54 | ||||||||||||||||||||
55 | ||||||||||||||||||||
56 | ||||||||||||||||||||
57 | ||||||||||||||||||||
58 | ||||||||||||||||||||
59 | ||||||||||||||||||||
60 | ||||||||||||||||||||
61 | ||||||||||||||||||||
62 | ||||||||||||||||||||
63 | ||||||||||||||||||||
64 | ||||||||||||||||||||
65 | ||||||||||||||||||||
66 | ||||||||||||||||||||
67 | ||||||||||||||||||||
68 | ||||||||||||||||||||
69 | ||||||||||||||||||||
70 | ||||||||||||||||||||
71 | ||||||||||||||||||||
72 | ||||||||||||||||||||
73 | ||||||||||||||||||||
74 | ||||||||||||||||||||
75 | ||||||||||||||||||||
76 | ||||||||||||||||||||
77 | ||||||||||||||||||||
78 | ||||||||||||||||||||
79 | ||||||||||||||||||||
80 | ||||||||||||||||||||
81 | ||||||||||||||||||||
82 | ||||||||||||||||||||
83 | ||||||||||||||||||||
84 | ||||||||||||||||||||
85 | ||||||||||||||||||||
86 | ||||||||||||||||||||
87 | ||||||||||||||||||||
88 | ||||||||||||||||||||
89 | ||||||||||||||||||||
90 | ||||||||||||||||||||
91 | ||||||||||||||||||||
92 | ||||||||||||||||||||
93 | ||||||||||||||||||||
94 | ||||||||||||||||||||
95 | ||||||||||||||||||||
96 | ||||||||||||||||||||
97 | ||||||||||||||||||||
98 | ||||||||||||||||||||
99 | ||||||||||||||||||||
100 |